Ultimately, metformin activates AMPK, exerting anti-tumorigenic properties in cancers by phosphorylating and activating two crucial tumor suppressors, TSC 1/2 and P53 (28, 65, 72, 73). This evidence concerns the gene TP53 and cancer.